EMA Recommends Granting a Marketing Authorisation Under Exceptional Circumstances for Moxetumomab Pasudotox
It is intended for the treatment of relapsed or refractory hairy cell leukaemia
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Granting a Marketing Authorisation for Generic Sunitinib
Sunitinib Accord is a generic of Sutent, which has been authorised in the EU since 2006
EMA Recommends Extension of Indications for Avelumab
New indication concerns the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma
EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib
It is intended for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer
EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan
It is intended for the treatment of metastatic HER2-positive breast cancer
EMA Recommends Extension of Indications for Pembrolizumab
New indication concerns the first-line treatment of metastatic MSI-H or dMMR colorectal cancer
TG4001 Therapeutic Vaccination Plus Avelumab-Mediated PD-L1 Blockade Improves Tumour Microenvironment in HPV-Positive Malignancies
This combination changes “cold” tumour microenvironments to “hot” in Human Papillomavirus-positive malignancies
Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and Safe in Recurrent Glioblastoma
Patients received intratumoural administration of ipilimumab plus nivolumab that was followed by intracavitary nivolumab plus nivolumab given intravenously
Promising Results Are Provided by Tebentafusp in Metastatic Uveal Melanoma
Metastatic uveal melanoma is a treatment-refractory tumour that is associated with poor prognosis and poses an urgent need for new treatments
Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma
Quality of life, as evaluated by patient reported outcomes, was an exploratory endpoint of CheckMate 743
Survival According Circulating Tumour DNA Status in the Study of Adjuvant Atezolizumab for High-Risk Muscle Invasive Urothelial Cancer
Post-surgical ctDNA-positivity in patients with MIUC associates with higher risk of disease recurrence and identifies patients that may benefit from adjuvant atezolizumab therapy
Haematologic Toxicity Not Increased with Immunochemotherapy Combinations Over Chemotherapy Treatment for Solid Tumours
Immunochemotherapy combinations have demonstrated improved efficacy over sole chemotherapy in diverse solid tumours